Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Advancing Affordable, Immune-Based Multi-Cancer Early Detection

Ziel

Cancer is the second leading cause of death in Europe, and its burden is expected to rise sharply, with the World Health Organization projecting a 77% increase in cases by 2050. Despite commitments to expand population-based screening, 50% of cancers are still detected at advanced stages and 70% of cancer deaths arise from cancers without available screening. Current multicancer detection tests, largely based on circulating tumour DNA (ctDNA), remain too insensitive for early-stage disease and too expensive for widespread use (~€875 per patient), making them unsuitable for population-scale implementation.
Enlighten®, developed by Proteotype Diagnostics, introduces a new approach to multicancer early detection (MCED), by measuring the host’s immune-driven proteomic response rather than scarce tumour-derived material. Using a simple fluorescence-based kit and an AI classifier, Enlighten® quantifies Protein Cross Sections directly from neat plasma. Independent validation shows high stage I sensitivity, with 95% overall sensitivity and 100% specificity across multiple solid tumours, at a price point compatible with decentralised, population-level screening.
The Enlighten Pre-Accelerator project will advance Enlighten® from TRL 5 to TRL 6 and BRL 4 to BRL 6 through AI model optimisation, multi-geography data harmonisation, and development of a clinician-ready digital interface. Cloud security, interoperability and SaMD documentation will be strengthened to meet IVDR and ISO 13485/IEC 62304 requirements. These activities will deliver a clinically verified, regulatory-ready platform and establish a clear pathway toward pivotal validation studies and EIC Accelerator funding.
The Enlighten Pre-Accelerator will deliver a CE-ready TRL6/BRL6 platform for affordable MCED. Enlighten® has the potential to become Europe’s first scalable MCED solution, reducing late-stage diagnoses, lowering healthcare expenditure, and enabling more equitable access to cancer prevention.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-CSA - HORIZON Coordination and Support Actions

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-WIDERA-2025-02

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

PROTEOTYPE DIAGNOSTICS UNIPESSOAL LDA
Netto-EU-Beitrag
€ 498 840,56
Adresse
RUA DR GOMES LEAL N3A
2560-331 TORRES VEDRAS
Portugal
KMU
Ja
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten